Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection
- Autores
- Mendizabal, Manuel; Ridruejo, Ezequiel; Piñero, Federico; Anders, Margarita; Padilla, Martín Jesus; Toro, Luis G.; Torre, Aldo; Montes, Pedro; Urzúa, Alvaro; Gonzalez Ballerga, Esteban; Silveyra, María Dolores; Michelato, Douglas; Díaz, Javier; Peralta, Mirta; Pages, Josefina; García, Sandro Ruiz; Gutierrez Lozano, Isabel; Macias, Yuridia; Cocozzella, Daniel; Chavez Tapia, Norberto; Tagle, Martín; Dominguez, Alejandra; Varón, Adriana; Vera Pozo, Emilia; Higuera de la Tijera, Fátima; Bustios, Carla; Conte, Damián; Escajadillo, Nataly; Rubinstein, Fernando Adrian; Tenorio, Laura
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Introduction and Objectives: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized patients with cirrhosis and to compare the performance of different prognostic models for predicting mortality. Patients: We performed a prospective cohort study including 2211 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through October 1, 2020 in 38 Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters of patients with and without cirrhosis. All patients were followed until discharge or death. We evaluated the prognostic performance of different scoring systems to predict mortality in patients with cirrhosis using ROC curves. Results: Overall, 4.6% (CI 3.7–5.6) subjects had cirrhosis (n = 96). Baseline Child-Turcotte-Pugh (CTP) class was assessed: CTP-A (23%), CTP-B (45%) and CTP-C (32%); median MELD-Na score was 19 (IQR 14−25). Mortality was 47% in patients with cirrhosis and 16% in patients without cirrhosis (P < .0001). Cirrhosis was independently associated with death [OR 3.1 (CI 1.9−4.8); P < .0001], adjusted by age, gender, and body mass index >30. The areas under the ROC curves for performance evaluation in predicting 28-days mortality for Chronic Liver Failure Consortium (CLIF-C), North American Consortium for the Study of End-Stage Liver Disease (NACSELD), CTP score and MELD-Na were 0.85, 0.75, 0.69, 0.67; respectively (P < .0001). Conclusions: SARS-CoV-2 infection is associated with elevated mortality in patients with cirrhosis. CLIFC had better performance in predicting mortality than NACSELD, CTP and MELD-Na in patients with cirrhosis and SARS-CoV-2 infection. Clinicaltrials.gov:NCT04358380.
Fil: Mendizabal, Manuel. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina
Fil: Ridruejo, Ezequiel. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Centro de Educación Médica e Investigaciones Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Piñero, Federico. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina
Fil: Anders, Margarita. Hospital Alemán; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina
Fil: Padilla, Martín Jesus. Hospital Nacional Guillermo Almenara Irigoyen; Perú
Fil: Toro, Luis G.. Fundación de Medellín y Rionegro; Colombia
Fil: Torre, Aldo. Instituto Nacional de Ciencias Médicas y Nutrición; México
Fil: Montes, Pedro. Hospital Nacional Daniel A. Carrión; Argentina
Fil: Urzúa, Alvaro. Universidad de Chile; Chile
Fil: Gonzalez Ballerga, Esteban. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Silveyra, María Dolores. Sanatorio Anchorena; Argentina
Fil: Michelato, Douglas. Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia; Brasil
Fil: Díaz, Javier. Hospital Nacional Edgardo Rebagliati Martins; Perú
Fil: Peralta, Mirta. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina
Fil: Pages, Josefina. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina
Fil: García, Sandro Ruiz. Hospital de Víctor Lazarte Echegaray; Perú
Fil: Gutierrez Lozano, Isabel. Centro Médico ABC; México
Fil: Macias, Yuridia. IMSS Hospital General Regional No. 1 “Dr. Carlos Mc Gregor Sánchez”; México
Fil: Cocozzella, Daniel. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Hospital Italiano de La Plata; Argentina
Fil: Chavez Tapia, Norberto. Medica Sur Clinic & Foundation; México
Fil: Tagle, Martín. Clínica Anglo-Americana; Perú
Fil: Dominguez, Alejandra. Hospital Padre Hurtado; Chile
Fil: Varón, Adriana. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Fundación Cardio Infantil; Colombia
Fil: Vera Pozo, Emilia. Hospital Regional Dr. Teodoro Maldonado Carbo del IESS; Ecuador
Fil: Higuera de la Tijera, Fátima. Hospital General de México “Dr. Eduardo Liceaga”; México
Fil: Bustios, Carla. Fundación Cardio Infantil; Colombia
Fil: Conte, Damián. Hospital Privado de Córdoba; Argentina
Fil: Escajadillo, Nataly. Universidad Austral; Argentina
Fil: Rubinstein, Fernando Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia; Brasil
Fil: Tenorio, Laura. Hospital Nacional Edgardo Rebagliati Martins; Perú - Materia
-
ACUTE-ON-CHRONIC LIVER FAILURE
CIRRHOSIS
CORONAVIRUS
COVID-19
DEATH
PANDEMIC - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/149753
Ver los metadatos del registro completo
id |
CONICETDig_47ff853ff4a64bc7d3ced181b495a67d |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/149753 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infectionMendizabal, ManuelRidruejo, EzequielPiñero, FedericoAnders, MargaritaPadilla, Martín JesusToro, Luis G.Torre, AldoMontes, PedroUrzúa, AlvaroGonzalez Ballerga, EstebanSilveyra, María DoloresMichelato, DouglasDíaz, JavierPeralta, MirtaPages, JosefinaGarcía, Sandro RuizGutierrez Lozano, IsabelMacias, YuridiaCocozzella, DanielChavez Tapia, NorbertoTagle, MartínDominguez, AlejandraVarón, AdrianaVera Pozo, EmiliaHiguera de la Tijera, FátimaBustios, CarlaConte, DamiánEscajadillo, NatalyRubinstein, Fernando AdrianTenorio, LauraACUTE-ON-CHRONIC LIVER FAILURECIRRHOSISCORONAVIRUSCOVID-19DEATHPANDEMIChttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Introduction and Objectives: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized patients with cirrhosis and to compare the performance of different prognostic models for predicting mortality. Patients: We performed a prospective cohort study including 2211 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through October 1, 2020 in 38 Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters of patients with and without cirrhosis. All patients were followed until discharge or death. We evaluated the prognostic performance of different scoring systems to predict mortality in patients with cirrhosis using ROC curves. Results: Overall, 4.6% (CI 3.7–5.6) subjects had cirrhosis (n = 96). Baseline Child-Turcotte-Pugh (CTP) class was assessed: CTP-A (23%), CTP-B (45%) and CTP-C (32%); median MELD-Na score was 19 (IQR 14−25). Mortality was 47% in patients with cirrhosis and 16% in patients without cirrhosis (P < .0001). Cirrhosis was independently associated with death [OR 3.1 (CI 1.9−4.8); P < .0001], adjusted by age, gender, and body mass index >30. The areas under the ROC curves for performance evaluation in predicting 28-days mortality for Chronic Liver Failure Consortium (CLIF-C), North American Consortium for the Study of End-Stage Liver Disease (NACSELD), CTP score and MELD-Na were 0.85, 0.75, 0.69, 0.67; respectively (P < .0001). Conclusions: SARS-CoV-2 infection is associated with elevated mortality in patients with cirrhosis. CLIFC had better performance in predicting mortality than NACSELD, CTP and MELD-Na in patients with cirrhosis and SARS-CoV-2 infection. Clinicaltrials.gov:NCT04358380.Fil: Mendizabal, Manuel. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; ArgentinaFil: Ridruejo, Ezequiel. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Centro de Educación Médica e Investigaciones Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Piñero, Federico. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; ArgentinaFil: Anders, Margarita. Hospital Alemán; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; ArgentinaFil: Padilla, Martín Jesus. Hospital Nacional Guillermo Almenara Irigoyen; PerúFil: Toro, Luis G.. Fundación de Medellín y Rionegro; ColombiaFil: Torre, Aldo. Instituto Nacional de Ciencias Médicas y Nutrición; MéxicoFil: Montes, Pedro. Hospital Nacional Daniel A. Carrión; ArgentinaFil: Urzúa, Alvaro. Universidad de Chile; ChileFil: Gonzalez Ballerga, Esteban. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Silveyra, María Dolores. Sanatorio Anchorena; ArgentinaFil: Michelato, Douglas. Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia; BrasilFil: Díaz, Javier. Hospital Nacional Edgardo Rebagliati Martins; PerúFil: Peralta, Mirta. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; ArgentinaFil: Pages, Josefina. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; ArgentinaFil: García, Sandro Ruiz. Hospital de Víctor Lazarte Echegaray; PerúFil: Gutierrez Lozano, Isabel. Centro Médico ABC; MéxicoFil: Macias, Yuridia. IMSS Hospital General Regional No. 1 “Dr. Carlos Mc Gregor Sánchez”; MéxicoFil: Cocozzella, Daniel. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Hospital Italiano de La Plata; ArgentinaFil: Chavez Tapia, Norberto. Medica Sur Clinic & Foundation; MéxicoFil: Tagle, Martín. Clínica Anglo-Americana; PerúFil: Dominguez, Alejandra. Hospital Padre Hurtado; ChileFil: Varón, Adriana. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Fundación Cardio Infantil; ColombiaFil: Vera Pozo, Emilia. Hospital Regional Dr. Teodoro Maldonado Carbo del IESS; EcuadorFil: Higuera de la Tijera, Fátima. Hospital General de México “Dr. Eduardo Liceaga”; MéxicoFil: Bustios, Carla. Fundación Cardio Infantil; ColombiaFil: Conte, Damián. Hospital Privado de Córdoba; ArgentinaFil: Escajadillo, Nataly. Universidad Austral; ArgentinaFil: Rubinstein, Fernando Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia; BrasilFil: Tenorio, Laura. Hospital Nacional Edgardo Rebagliati Martins; PerúMexican Association of Hepatology2021-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/149753Mendizabal, Manuel; Ridruejo, Ezequiel; Piñero, Federico; Anders, Margarita; Padilla, Martín Jesus; et al.; Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection; Mexican Association of Hepatology; Annals of Hepatology; 25; 100350; 11-2021; 1-91665-2681CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S1665268121000491info:eu-repo/semantics/altIdentifier/doi/10.1016/j.aohep.2021.100350info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:05:53Zoai:ri.conicet.gov.ar:11336/149753instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:05:53.534CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection |
title |
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection |
spellingShingle |
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection Mendizabal, Manuel ACUTE-ON-CHRONIC LIVER FAILURE CIRRHOSIS CORONAVIRUS COVID-19 DEATH PANDEMIC |
title_short |
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection |
title_full |
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection |
title_fullStr |
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection |
title_full_unstemmed |
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection |
title_sort |
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection |
dc.creator.none.fl_str_mv |
Mendizabal, Manuel Ridruejo, Ezequiel Piñero, Federico Anders, Margarita Padilla, Martín Jesus Toro, Luis G. Torre, Aldo Montes, Pedro Urzúa, Alvaro Gonzalez Ballerga, Esteban Silveyra, María Dolores Michelato, Douglas Díaz, Javier Peralta, Mirta Pages, Josefina García, Sandro Ruiz Gutierrez Lozano, Isabel Macias, Yuridia Cocozzella, Daniel Chavez Tapia, Norberto Tagle, Martín Dominguez, Alejandra Varón, Adriana Vera Pozo, Emilia Higuera de la Tijera, Fátima Bustios, Carla Conte, Damián Escajadillo, Nataly Rubinstein, Fernando Adrian Tenorio, Laura |
author |
Mendizabal, Manuel |
author_facet |
Mendizabal, Manuel Ridruejo, Ezequiel Piñero, Federico Anders, Margarita Padilla, Martín Jesus Toro, Luis G. Torre, Aldo Montes, Pedro Urzúa, Alvaro Gonzalez Ballerga, Esteban Silveyra, María Dolores Michelato, Douglas Díaz, Javier Peralta, Mirta Pages, Josefina García, Sandro Ruiz Gutierrez Lozano, Isabel Macias, Yuridia Cocozzella, Daniel Chavez Tapia, Norberto Tagle, Martín Dominguez, Alejandra Varón, Adriana Vera Pozo, Emilia Higuera de la Tijera, Fátima Bustios, Carla Conte, Damián Escajadillo, Nataly Rubinstein, Fernando Adrian Tenorio, Laura |
author_role |
author |
author2 |
Ridruejo, Ezequiel Piñero, Federico Anders, Margarita Padilla, Martín Jesus Toro, Luis G. Torre, Aldo Montes, Pedro Urzúa, Alvaro Gonzalez Ballerga, Esteban Silveyra, María Dolores Michelato, Douglas Díaz, Javier Peralta, Mirta Pages, Josefina García, Sandro Ruiz Gutierrez Lozano, Isabel Macias, Yuridia Cocozzella, Daniel Chavez Tapia, Norberto Tagle, Martín Dominguez, Alejandra Varón, Adriana Vera Pozo, Emilia Higuera de la Tijera, Fátima Bustios, Carla Conte, Damián Escajadillo, Nataly Rubinstein, Fernando Adrian Tenorio, Laura |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
ACUTE-ON-CHRONIC LIVER FAILURE CIRRHOSIS CORONAVIRUS COVID-19 DEATH PANDEMIC |
topic |
ACUTE-ON-CHRONIC LIVER FAILURE CIRRHOSIS CORONAVIRUS COVID-19 DEATH PANDEMIC |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Introduction and Objectives: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized patients with cirrhosis and to compare the performance of different prognostic models for predicting mortality. Patients: We performed a prospective cohort study including 2211 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through October 1, 2020 in 38 Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters of patients with and without cirrhosis. All patients were followed until discharge or death. We evaluated the prognostic performance of different scoring systems to predict mortality in patients with cirrhosis using ROC curves. Results: Overall, 4.6% (CI 3.7–5.6) subjects had cirrhosis (n = 96). Baseline Child-Turcotte-Pugh (CTP) class was assessed: CTP-A (23%), CTP-B (45%) and CTP-C (32%); median MELD-Na score was 19 (IQR 14−25). Mortality was 47% in patients with cirrhosis and 16% in patients without cirrhosis (P < .0001). Cirrhosis was independently associated with death [OR 3.1 (CI 1.9−4.8); P < .0001], adjusted by age, gender, and body mass index >30. The areas under the ROC curves for performance evaluation in predicting 28-days mortality for Chronic Liver Failure Consortium (CLIF-C), North American Consortium for the Study of End-Stage Liver Disease (NACSELD), CTP score and MELD-Na were 0.85, 0.75, 0.69, 0.67; respectively (P < .0001). Conclusions: SARS-CoV-2 infection is associated with elevated mortality in patients with cirrhosis. CLIFC had better performance in predicting mortality than NACSELD, CTP and MELD-Na in patients with cirrhosis and SARS-CoV-2 infection. Clinicaltrials.gov:NCT04358380. Fil: Mendizabal, Manuel. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina Fil: Ridruejo, Ezequiel. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Centro de Educación Médica e Investigaciones Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Piñero, Federico. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina Fil: Anders, Margarita. Hospital Alemán; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina Fil: Padilla, Martín Jesus. Hospital Nacional Guillermo Almenara Irigoyen; Perú Fil: Toro, Luis G.. Fundación de Medellín y Rionegro; Colombia Fil: Torre, Aldo. Instituto Nacional de Ciencias Médicas y Nutrición; México Fil: Montes, Pedro. Hospital Nacional Daniel A. Carrión; Argentina Fil: Urzúa, Alvaro. Universidad de Chile; Chile Fil: Gonzalez Ballerga, Esteban. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina Fil: Silveyra, María Dolores. Sanatorio Anchorena; Argentina Fil: Michelato, Douglas. Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia; Brasil Fil: Díaz, Javier. Hospital Nacional Edgardo Rebagliati Martins; Perú Fil: Peralta, Mirta. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina Fil: Pages, Josefina. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina Fil: García, Sandro Ruiz. Hospital de Víctor Lazarte Echegaray; Perú Fil: Gutierrez Lozano, Isabel. Centro Médico ABC; México Fil: Macias, Yuridia. IMSS Hospital General Regional No. 1 “Dr. Carlos Mc Gregor Sánchez”; México Fil: Cocozzella, Daniel. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Hospital Italiano de La Plata; Argentina Fil: Chavez Tapia, Norberto. Medica Sur Clinic & Foundation; México Fil: Tagle, Martín. Clínica Anglo-Americana; Perú Fil: Dominguez, Alejandra. Hospital Padre Hurtado; Chile Fil: Varón, Adriana. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Fundación Cardio Infantil; Colombia Fil: Vera Pozo, Emilia. Hospital Regional Dr. Teodoro Maldonado Carbo del IESS; Ecuador Fil: Higuera de la Tijera, Fátima. Hospital General de México “Dr. Eduardo Liceaga”; México Fil: Bustios, Carla. Fundación Cardio Infantil; Colombia Fil: Conte, Damián. Hospital Privado de Córdoba; Argentina Fil: Escajadillo, Nataly. Universidad Austral; Argentina Fil: Rubinstein, Fernando Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia; Brasil Fil: Tenorio, Laura. Hospital Nacional Edgardo Rebagliati Martins; Perú |
description |
Introduction and Objectives: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized patients with cirrhosis and to compare the performance of different prognostic models for predicting mortality. Patients: We performed a prospective cohort study including 2211 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through October 1, 2020 in 38 Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters of patients with and without cirrhosis. All patients were followed until discharge or death. We evaluated the prognostic performance of different scoring systems to predict mortality in patients with cirrhosis using ROC curves. Results: Overall, 4.6% (CI 3.7–5.6) subjects had cirrhosis (n = 96). Baseline Child-Turcotte-Pugh (CTP) class was assessed: CTP-A (23%), CTP-B (45%) and CTP-C (32%); median MELD-Na score was 19 (IQR 14−25). Mortality was 47% in patients with cirrhosis and 16% in patients without cirrhosis (P < .0001). Cirrhosis was independently associated with death [OR 3.1 (CI 1.9−4.8); P < .0001], adjusted by age, gender, and body mass index >30. The areas under the ROC curves for performance evaluation in predicting 28-days mortality for Chronic Liver Failure Consortium (CLIF-C), North American Consortium for the Study of End-Stage Liver Disease (NACSELD), CTP score and MELD-Na were 0.85, 0.75, 0.69, 0.67; respectively (P < .0001). Conclusions: SARS-CoV-2 infection is associated with elevated mortality in patients with cirrhosis. CLIFC had better performance in predicting mortality than NACSELD, CTP and MELD-Na in patients with cirrhosis and SARS-CoV-2 infection. Clinicaltrials.gov:NCT04358380. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-11 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/149753 Mendizabal, Manuel; Ridruejo, Ezequiel; Piñero, Federico; Anders, Margarita; Padilla, Martín Jesus; et al.; Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection; Mexican Association of Hepatology; Annals of Hepatology; 25; 100350; 11-2021; 1-9 1665-2681 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/149753 |
identifier_str_mv |
Mendizabal, Manuel; Ridruejo, Ezequiel; Piñero, Federico; Anders, Margarita; Padilla, Martín Jesus; et al.; Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection; Mexican Association of Hepatology; Annals of Hepatology; 25; 100350; 11-2021; 1-9 1665-2681 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S1665268121000491 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.aohep.2021.100350 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Mexican Association of Hepatology |
publisher.none.fl_str_mv |
Mexican Association of Hepatology |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613900588285952 |
score |
13.070432 |